Acquisitions27 May 2026, 06:22 pm
Hemant Surgical to Acquire 66.66% Stake in Lifesenz Cancer Labs
AI Summary
Hemant Surgical Industries Ltd has entered into a Share Purchase Agreement (SPA) on May 27, 2026, to acquire 66.66% equity shareholding of Lifesenz Cancer Research Labs Private Limited, Mumbai. The acquisition, subject to certain conditions, will make Lifesenz Cancer Research Labs a subsidiary of Hemant Surgical. The cost of acquisition is ₹19,99,80,000 in cash. This acquisition is aimed at expanding Hemant Surgical's presence in the healthcare and cancer diagnostic support segment. The target entity's turnover for FY 24-25 was ₹56.75 Lakhs, with a net loss of ₹(74.76) Lakhs and a net worth of ₹(221.84) Lakhs.
Key Highlights
- Hemant Surgical acquires 66.66% stake in Lifesenz Cancer Research Labs for ₹19,99,80,000.
- Lifesenz Cancer Labs will become a subsidiary post-acquisition.
- The acquisition is a related party transaction, done at arm's length.
- Lifesenz Cancer Labs' FY24-25 turnover was ₹56.75 Lakhs with a net loss of ₹(74.76) Lakhs.
- The acquisition is expected to be completed on or before September 30, 2026.